Now live: Pro — the full 13F research suite for serious investorsSee pricing →
← Tracker

Institutional

Cormorant Asset Management, LP

CIK 0001583977
$1.99B
Reported AUM
46
Positions
Q1 2026
Period
2026-05-15
Filed

The Brief · Cormorant Asset Management, LP · Q1 2026

AI · grounded in 13F

Cormorant Asset Management, LP exited its position in QQQ, reducing exposure by $153.6M. The fund also closed positions in IWM and XBI, totaling $123.1M and $121.9M respectively. On the buy side, the manager established new positions in ERAS for $93.8M and DNTH for $79.7M. Additionally, the fund increased its holdings in ALMS by 8.6%.

Portfolio · Q1 2026

PRAX$285.3MBBOT$160.0MEYPT$106.5MEWTX$102.7MERASRAPPALMSABVXMLTXDNTHDRUGOLMAOther$672.4MCL

Top holdings

#StockIssuerPriceDay %1Y Gr.5Y Gr.Value% of bookΔ shares (QoQ)Status
1PRAXPRAXIS PRECISION MEDICINES I$307.755.75%453.36%0.42%$285.3M14.33%HELD
2BBOTBRIDGEBIO ONCOLOGY THERAPEUT$8.503.22%-19.45%-19.18%$160.0M8.04%HELD
3EYPTEYEPOINT INC$12.867.89%22.76%8.96%$106.5M5.35%HELD
4EWTXEDGEWISE THERAPEUTICS INC$41.123.45%177.78%150.95%$102.7M5.16%HELD
5ERASERASCA INC$18.685.42%1243.88%-21.87%$93.8M4.71%HELD
6RAPPRAPPORT THERAPEUTICS INC$42.784.49%202.33%88.29%$92.5M4.65%HELD
7ALMSALUMIS INC$28.959.74%563.92%122.93%$87.0M4.37%HELD
8ABVXABIVAX SA$124.334.62%65.18%1070.84%$84.6M4.25%HELD
9MLTXMOONLAKE IMMUNOTHERAPEUTICS$18.993.32%-64.74%88.87%$83.5M4.19%HELD
10DNTHDIANTHUS THERAPEUTICS INC$112.648.21%447.06%10.00%$79.7M4.00%HELD
11DRUGBRIGHT MINDS BIOSCIENCES INC$74.635.02%120.61%179.65%$77.3M3.88%HELD
12OLMAOLEMA PHARMACEUTICALS INC$11.825.63%108.82%-62.80%$65.6M3.29%HELD
13BBIOBRIDGEBIO PHARMA INC$82.14-1.68%72.55%63.11%$63.1M3.17%HELD
14BIOABIOAGE LABS INC$24.8511.99%466.02%-1.19%$50.6M2.54%HELD
15CNTACENTESSA PHARMACEUTICALS PLC0.00%$41.7M2.09%HELD
16DMRADAMORA THERAPEUTICS INC$29.213.11%811.39%-73.74%$39.5M1.98%HELD
17MBXMBX BIOSCIENCES INC$66.463.91%378.44%187.27%$33.4M1.68%HELD
18INSMINSMED INC$101.49-1.58%-7.34%259.18%$31.1M1.56%HELD
19NAMSNEWAMSTERDAM PHARMA COMPANY$28.461.97%33.74%194.62%$30.4M1.53%HELD
20TNGXTANGO THERAPEUTICS INC$27.576.65%299.69%124.23%$29.8M1.50%HELD
21PHVSPHARVARIS N V$33.883.86%67.35%65.78%$28.3M1.42%HELD
22ORKAORUKA THERAPEUTICS INC$97.8611.12%619.56%390.71%$26.2M1.31%HELD
23AGMBAGOMAB THERAPEUTICS NV$12.762.90%-12.94%21.59%$25.9M1.30%HELD
24MAZEMAZE THERAPEUTICS INC$27.631.32%85.44%125.92%$22.4M1.12%HELD
25CRBPCORBUS PHARMACEUTICALS HLDGS$9.051.46%-2.79%-76.61%$22.0M1.11%HELD
26ASNDUSDASCENDIS PHARMA A/S$21.7M1.09%HELD
27ROIVROIVANT SCIENCES LTD$34.525.02%202.21%243.52%$20.8M1.04%HELD
28ANLADLAI NORTYE LTD$13.007.35%796.55%61.49%$20.1M1.01%HELD
29430TERNS PHARMACEUTICALS INC$15.8M0.79%HELD
30TARSTARSUS PHARMACEUTICALS INC$59.541.74%43.71%121.32%$15.8M0.79%HELD
31BHVNBIOHAVEN LTD$13.822.90%$14.9M0.75%HELD
32CABACABALETTA BIO INC$2.723.82%$14.8M0.74%HELD
33HLXCHELIX ACQUISITION CORP III$10.510.00%$13.2M0.66%HELD
34ARQTARCUTIS BIOTHERAPEUTICS INC$27.990.47%$10.6M0.53%HELD
35SNSESENSEI BIOTHERAPEUTICS INC$9.7M0.48%HELD
36CRNXCRINETICS PHARMACEUTICALS IN$83.63-0.30%$9.1M0.46%HELD
37ZURAZURA BIO LTD$5.544.33%$8.6M0.43%HELD
38AXSMAXSOME THERAPEUTICS INC.$234.643.17%$8.5M0.42%HELD
39GPCRSTRUCTURE THERAPEUTICS INC$49.474.48%$8.4M0.42%HELD
40COGTCOGENT BIOSCIENCES INC$41.364.52%$7.7M0.39%HELD
41GLUEMONTE ROSA THERAPEUTICS INC$22.685.19%$6.6M0.33%HELD
42ARWRARROWHEAD PHARMACEUTICALS IN$87.321.28%$6.3M0.31%HELD
43PCVXVAXCYTE INC$55.965.62%$5.8M0.29%HELD
44AMLXAMYLYX PHARMACEUTICALS INC$20.755.17%$4.9M0.24%HELD
45RLYBRALLYBIO CORP$16.070.69%$3.6M0.18%HELD
46CNTXCONTEXT THERAPEUTICS INC$0.61-1.62%$1.4M0.07%HELD

Source: SEC EDGAR · accession 0001583977-26-000002. 13F discloses long positions only — shorts, foreign equities, and options are excluded.